New! Sign up for our free email newsletter.
Science News
from research organizations

Indications of Alzheimer's disease may be evident decades before first signs of cognitive impairment

Date:
March 28, 2011
Source:
The Mount Sinai Hospital / Mount Sinai School of Medicine
Summary:
Researchers have found that patients with Alzheimer's disease have lower glucose utilization in the brain than those with normal cognitive function, and that those decreased levels may be detectable approximately 20 years prior to the first symptoms of Alzheimer's disease. This new finding could lead to the development of novel therapies to prevent the eventual onset of Alzheimer's.
Share:
FULL STORY

Researchers at Mount Sinai School of Medicine have found that patients with Alzheimer's disease have lower glucose utilization in the brain than those with normal cognitive function, and that those decreased levels may be detectable approximately 20 years prior to the first symptoms of Alzheimer's disease. This new finding could lead to the development of novel therapies to prevent the eventual onset of Alzheimer's.

The study is published online in the journal Translational Neuroscience.

Using mice modified to develop Alzheimer's disease, the research team found that when β-amyloid, an abnormal protein linked to Alzheimer's disease, starts to become detectable in the brain in its soluble toxic form, the mitochondria, or "power plants" of the cell where glucose is converted into energy, became impaired. Within the equivalent of about 20 human years, mice with decreased energy metabolism developed signs of Alzheimer's disease such as cognitive defects and impairment of the synaptic terminal, the area of brain cells important in memory formation.

"This evidence in mice validates that the diagnosis of probable Alzheimer's disease may be the end result of impairment in brain cell energy production," said the study's lead author, Giulio M. Pasinetti, MD, PhD, The Saunder Family Professor in Neurology, and Professor of Psychiatry, Geriatrics, and Adult Development at Mount Sinai School of Medicine. "Identifying that mitochondrial impairment is evident years earlier than cognitive defects is a major breakthrough."

"This new evidence could revolutionize the way we design interventions," said Merina T. Varghese, MD, co-author of the study and Postdoctoral Fellow in Neurology at Mount Sinai School of Medicine. "This study sets the stage for the development of potential novel preventions or therapies to apply in humans, even when they have normal cognitive function, to prevent the eventual onset of Alzheimer's disease."


Story Source:

Materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine. Note: Content may be edited for style and length.


Journal Reference:

  1. Merina Varghese, Wei Zhao, Jun Wang, Alice Cheng, Xianjuan Qian, Amna Chaudhry, Lap Ho, Giulio Maria Pasinetti. Mitochondrial bioenergetics is defective in presymptomatic Tg2576 AD Mice. Translational Neuroscience, 2011; 2 (1): 1 DOI: 10.2478/s13380-011-0011-8

Cite This Page:

The Mount Sinai Hospital / Mount Sinai School of Medicine. "Indications of Alzheimer's disease may be evident decades before first signs of cognitive impairment." ScienceDaily. ScienceDaily, 28 March 2011. <www.sciencedaily.com/releases/2011/03/110328161854.htm>.
The Mount Sinai Hospital / Mount Sinai School of Medicine. (2011, March 28). Indications of Alzheimer's disease may be evident decades before first signs of cognitive impairment. ScienceDaily. Retrieved December 21, 2024 from www.sciencedaily.com/releases/2011/03/110328161854.htm
The Mount Sinai Hospital / Mount Sinai School of Medicine. "Indications of Alzheimer's disease may be evident decades before first signs of cognitive impairment." ScienceDaily. www.sciencedaily.com/releases/2011/03/110328161854.htm (accessed December 21, 2024).

Explore More

from ScienceDaily

RELATED STORIES